Q1 2025 Recap: Psychiatry

At the start of this week, HCPLive sat down with Steve Levine, MD, from Compass Pathways, to recap Q1 psychiatry highlights and preview Q2. Although the psychiatry pipeline may be “dry,” as Levine put it, Q1 had 5 regulatory updates from the US Food and Drug Administration (FDA) and 3 trials showcasing topline results for phase 2 and 3 trials in opioid use disorder (OUD), bipolar disorder, treatment-resistant depression, PTSD, ADHD, and schizophrenia.